A Case Report of Dapagliflozin-Induced Nodular Vasculitis

被引：0

作者：

Kocabas, Muhammet ^{[1
]}

Yarar, Zeliha ^{[1
]}

Cordan, Ilker ^{[2
]}

Can, Mustafa ^{[1
]}

Caliskan Burgucu, Hatice ^{[1
]}

Aydemir, Harun ^{[3
]}

Karakose, Melia ^{[1
]}

Kulaksizoglu, Mustafa ^{[1
]}

Karakurt, Feridun ^{[1
]}

机构：

[1] Necmettin Erbakan Univ, Meram Fac Med, Dept Endocrinol & Metab, Konya, Turkey

[2] Edirne Sultan 1 Murat State Hosp, Clin Endocrinol & Metab, Edirne, Turkey

[3] Necmettin Erbakan Univ, Meram Fac Med, Dept Rheumatol, Konya, Turkey

来源：

TURKISH JOURNAL OF ENDOCRINOLOGY AND METABOLISM | 2021年 / 25卷 / 01期

关键词：

Nodular vasculitis; dapagliflozin; antinuclear antibodies; sodium-glucose cotransporter-2 inhibitors; diabetes mellitus; SGLT2; INHIBITORS; DIAGNOSIS;

D O I：

10.25179/tjem.2020-80188

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Nodular vasculitis (NV), first described by Montgomery in 1945 for erythema induratum-like lesions, is a rare form of panniculitis that is particularly localized on the calves. Characterized by plaques and erythematous nodules, NV may often show ulceration and draining. It is known as a reactive disease associated with many causative factors. Several NV cases due to infectious or non-infectious causative factors have been reported, but no case of NV due to sodium-glucose cotransporter-2 inhibitors (SGLT2i) has yet been reported. In this case report, we presented a case diagnosed with NV, who presented with tender, erythematous, eroded plaques with hemorrhagic-purulent discharge on both legs during treatment with dapagliflozin (an SGLT2i).

引用

页码：129 / 132

页数：4

共 18 条

[1] Nodular vasculitis associated with lung adenocarcinoma
Borges, Ana Sofia
Brasileiro, Ana
Apetato, Margarida
[J]. ANAIS BRASILEIROS DE DERMATOLOGIA, 2018, 93 (06) : 887 - 889
[2] Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor
Fralick, Michael
Schneeweiss, Sebastian
Patorno, Elisabetta
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (23) : 2300 - 2302
[3] SGLT2 Inhibitors: A New Emerging Therapeutic Class in the Treatment of Type 2 Diabetes Mellitus
Ghosh, Raktim Kumar
Ghosh, Samhati Mondal
Chawla, Shalini
Jasdanwala, Sarfaraz Abdeli
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (04) : 457 - 463
[4] Erythema nodosum and erythema induratum (nodular vasculitis): diagnosis and management
Gilchrist, Heidi
Patterson, James W.
[J]. DERMATOLOGIC THERAPY, 2010, 23 (04) : 320 - 327
[5] Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin
Haas, B.
Eckstein, N.
Pfeifer, V.
Mayer, P.
Hass, M. D. S.
[J]. NUTRITION & DIABETES, 2014, 4 : e143 - e143
[6] Acute kidney injury from SGLT2 inhibitors: potential mechanisms
Hahn, Kai
Ejaz, A. Ahsan
Kanbay, Mehmet
Lanaspa, Miguel A.
Johnson, Richard J.
[J]. NATURE REVIEWS NEPHROLOGY, 2016, 12 (12) : 711 - 712
[7] Nodular vasculitis as a paraneoplastic presentation?
Khachemoune, A
Longo, MI
Phillips, TJ
[J]. INTERNATIONAL JOURNAL OF DERMATOLOGY, 2003, 42 (08) : 639 - 642
[8] Erythema Induratum (Nodular Vasculitis) Associated With Crohn's Disease: A Rare Type of Metastatic Crohn's Disease
Misago, Noriyuki
Narisawa, Yutaka
[J]. AMERICAN JOURNAL OF DERMATOPATHOLOGY, 2012, 34 (03) : 325 - 329
[9] MONTGOMERY RM, 1948, ARCH DERMATOL SYPH, V57, P580
[10] Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, Bruce
Perkovic, Vlado
Mahaffey, Kenneth W.
de Zeeuw, Dick
Fulcher, Greg
Erondu, Ngozi
Shaw, Wayne
Law, Gordon
Desai, Mehul
Matthews, David R.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (07) : 644 - 657

← 1 2 →